Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

FRAgile X syndrome Clinical trial: Unravelling the science behind this Rare disease in Europe

Project description

New treatment for Fragile X syndrome and other neurodevelopmental disorders

Fragile X syndrome is the leading inherited cause of intellectual disability, affecting around 1.8 million people worldwide. Despite decades of research, there is still no cure. For maximum neural development and social inclusion, early intervention is required. The EIC-funded FRAXCURE project focuses on CTH120, a novel drug designed to restore the brain's ability to form and reorganise neuronal connections. CTH120 has already demonstrated safety and tolerability in phase I clinical trials, and FRAXCURE will undertake a phase II clinical trial in both children and adults with Fragile X syndrome. Project results are anticipated to accelerate development of CTH120 for Fragile X syndrome and other neurodevelopmental disorders, including Rett syndrome, Down syndrome and autism spectrum disorder.

Objective

CONNECTA Therapeutics is a clinical biotech company developing new treatments for unmet Central Nervous System medical needs associated with neuroplasticity dysfunction, such as Fragile X Syndrome (FXS), a neurodevelopmental rare disease without a cure affecting around 1.8 M patients worldwide. FXS is responsible for 30% of intellectual disability and cognitive deterioration in both males and females, starting at paediatric age and chronically persisting for life, impacting in learning abilities, attention problems, hyperactivity, autism and social impairments. Early intervention in children is crucial to provide the greatest chance of developing a full range of neurodevelopmental skills, and more opportunities for their social inclusion.

Neuroplasticity modulation addressed by the network pharmacology approach is the core of CONNECTA’s technology. Particularly, CTH120, an excellent neuroplasticity modulator, is a new investigational medicinal product designed as an effective cure for both adults and children. This patented and proprietary technology has already succeeded in Phase I clinical trial demonstrating safety, tolerability and pharmacokinetics in humans, and its efficacy will be validated through the FRAXCURE project in the corresponding Phase II clinical trials targeting FXS paediatric and adult patients, including women with childbearing potential.

CONNECTA’s technology expands to other neurodevelopmental diseases, such as Rett syndrome, Down syndrome, and autism spectrum disorder, currently under preclinical testing by CONNECTA. Therefore, the success of the FRAXCURE project will boost the development of medicines for neurodevelopmental diseases for children and adults in Europe. Likewise, FRAXCURE will position CONNECTA as a leading biotech in the already highly successful research-based European pharmaceutical sector while reinforcing the competitiveness of the European Union in a key strategic technological field.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

CONNECTA THERAPEUTICS SL
Net EU contribution
€ 2 499 999,00
Address
CALLE BALDIRI REIXAC 10
08028 Barcelona
Spain
SME
Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data